Page 2 - Activating Construct News Today

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA. ​The Agreement, which will terminate effectiv...

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has

KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for poster presentation at the European Society for...

Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society Annual Meeting and the European Society for Medical Oncology in the fall Enrollment for HPN328 ...

Wang, who joins Harpoon from Hummingbird Bioscience, has a background of 15 years in biopharma business development and finance.

Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) have been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 […]

Harpoon Therapeutics (NASDAQ:HARP – Get Rating) and Codiak BioSciences (NASDAQ:CDAK – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations. Insider and Institutional Ownership 65.5% of Harpoon Therapeutics shares […]

Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) have received an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target […]

Precision BioSciences (NASDAQ:DTIL – Get Rating) and Harpoon Therapeutics (NASDAQ:HARP – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings. Earnings & Valuation This table compares Precision BioSciences and […]

Harpoon Therapeutics (NASDAQ:HARP – Get Rating)‘s stock had its “reiterates” rating reiterated by equities research analysts at 500.com in a note issued to investors on Monday, Benzinga reports. Several other analysts also recently weighed in on the company. HC Wainwright dropped their price objective on Harpoon Therapeutics from $7.00 to $4.50 and set a “buy” […]